Sangamo BioSciences | SGMO - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Alaunos Therapeutics USD 1.07M 215K 2023-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Bayer EUR 675M 87M 2025-12
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Cipla INR 170.3M 39M 2026-06
Compugen USD 1.35M 399K 2026-03
CSL USD 215M 111M 2025-12
Gilead Sciences USD 247M 7M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
Grifols EUR 156.07M 31.46M 2025-09
Ionis Pharmaceuticals USD 18M 1000K 2026-06
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.55M 66K 2026-03
Merck USD 525M 46M 2026-06
Novartis USD 462M 119M 2026-06
Omeros USD 4.05M 5.16M 2024-09
Pfizer USD 667M 4M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 287M 109M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Tectonic Therapeutic USD 246.58M 246.56M 2026-03
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12